Severe Respiratory Syncytial Virus Bronchiolitis

• DOI: 10.1097/01.inf.0000145406.74341.c7
• Publication Date: 2022-09-02T17:06:57Z
• Authors: Marianne Grimaldi; Béatrice Gouyon; Francis Michaut; Frédéric Huet; Jean-Bernard Gouyon
• Keywords: Palivizumab; Bronchopulmonary Dysplasia; Pneumovirus

Background: The efficacy of palivizumab prophylaxis after bronchopulmonary dysplasia (BPD) has been demonstrated in a single placebo-controlled trial. Concern emerged about the degree palivizumab. This study was designed to determine administration premature infants with gestational age ≤32 weeks, past history BPD and younger than 6 months at start epidemic. Methods: Prospective observational respiratory syncytial virus (RSV) bronchiolitis requiring hospitalization Burgundy (12 hospitals) from December 1 April 30 next year during 3 successive epidemic seasons (1999-2000, 2000-2001 2001-2002). regional perinatal database provided epidemiologic characteristics population as whole cohorts children risk for severe RSV infection born between 15 January 31 following year. Palivizumab used 2001-2002 periods only. Results: epidemics included respectively 377, 310 328 differed significantly by proportion severely (3.2% versus 0.7 0.3%). In cohort 1999-2000, 2001-2002, rate decreased 12 26 2 17 (46.2% 11.8 3.8%; P < 0.01). Sixteen 23 weeks had treated years 2001-2002. Conclusions: strongly supports prevention BPD.